Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 04, 2015 7:17 PM ET


Company Overview of Acceleron Pharma, Inc.

Key Executives for Acceleron Pharma, Inc.

NameBoard RelationshipsTitleAge
John L. Knopf Ph.D.12 RelationshipsFounder, Chief Executive Officer, President and Director63
Thomas P. Maniatis Ph.D.26 RelationshipsCo-Founder, Chairman of Scientific Advisory Board, Director and Member of Compensation Committee72
Mark Ptashne Ph.D.29 RelationshipsCo-Founder and Member of Scientific Advisory Board--
Kevin F. McLaughlin 9 RelationshipsChief Financial Officer, Senior Vice President and Treasurer59
Steven D. Ertel No RelationshipsChief Operating Officer and Executive Vice President46
View More Key Executives

Acceleron Pharma, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Francois Nader M.D., M.B.A. 56 RelationshipsNPS Allelix, Corp.58
John L. Knopf Ph.D. 12 RelationshipsAcceleron Pharma, Inc.63
Thomas P. Maniatis Ph.D. 26 RelationshipsAcceleron Pharma, Inc.72
Mark Ptashne Ph.D. 29 RelationshipsAcceleron Pharma, Inc.--
Jean M. George 61 RelationshipsLightstone Ventures57
View All Board Members

Acceleron Pharma, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee Terrence C. Kearney32 Relationships2 Executives
Compensation Committee Joseph S. Zakrzewski92 Relationships3 Executives
Nominating Committee Jean M. George61 Relationships1 Executives
Corporate Governance Committee Jean M. George61 Relationships1 Executives
Advisory Board Ph.D.Thomas P. Maniatis26 Relationships4 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


  Industry Range
Not meaningful
Total Short Term Compensation$460.0K
Total Value of Options
Compensation as of Fiscal Year
Acceleron Pharma, Inc. CEO Compensation
Industry Average


PURE Bioscience, Inc. Announces Executive Changes
July 31, 2015 1:49 PM ET
China Ludao Technology Company Limited Announces Change in Directorships
July 31, 2015 11:46 AM ET
Carewell Industries Limited Announces Management Changes
July 31, 2015 10:03 AM ET
Aunt Fannie's Appoints Mark Haas to Advisory Board
July 31, 2015 8:56 AM ET
The Procter & Gamble Company Announces Executive Changes
July 28, 2015 9:53 AM ET

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Acceleron Pharma, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at